Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-1110-08 Phase IIa Trial in Social Anxiety Disorder
jRCT2031240578Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing ONO-1110 once daily with Placebo once daily (2 arms). Primary endpoint: Change in total LSAS-J score from baseline. Started Jan 2025; status: completed.
02
Drugs
ONO-1110
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on jRCT2031240578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240578.